FDA Panel Backs Pfizer RSV Vaccine for Older Americans

WEDNESDAY, March 1, 2023 -- In a tight vote, U.S. Food and Drug Administration advisers on Tuesday recommended the approval of a respiratory syncytial virus (RSV) vaccine that could be used in Americans ages 60 years and older.
The vaccine, known as...